Budipine Hydrochloride

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 329212

CAS#: 63661-61-0 (HCl)

Description: Budipine, also known as BY-701 and Parkinsan, is a non-dopaminergic antiparkinsonian drug. The primary action of budipine is an indirect dopaminergic effect as shown by facilitation of dopamine (DA) release, inhibition of monoamine oxidase type B (MAO-B) and of DA (re) up-take and stimulation of aromatic L-amino acid decarboxylase (AADC), which in sum might be responsible for enhancing the endogenous dopaminergic activity.


Price and Availability

Size
Price

Size
Price

Size
Price

Budipine Hydrochloride (BY-701, Parkinsan) is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 329212
Name: Budipine Hydrochloride
CAS#: 63661-61-0 (HCl)
Chemical Formula: C21H28ClN
Exact Mass:
Molecular Weight: 329.912
Elemental Analysis: C, 76.45; H, 8.56; Cl, 10.75; N, 4.25


Related CAS #: 57982-78-2(free base)   63661-61-0(HCl)  

Synonym: Budipine Hydrochloride; BY-701; BY 701; BY701; Parkinsan

IUPAC/Chemical Name: 1-(tert-butyl)-4,4-diphenylpiperidin-1-ium chloride

InChi Key: USUUKNCFNKZGEY-UHFFFAOYSA-N

InChi Code: InChI=1S/C21H27N.ClH/c1-20(2,3)22-16-14-21(15-17-22,18-10-6-4-7-11-18)19-12-8-5-9-13-19;/h4-13H,14-17H2,1-3H3;1H

SMILES Code: CC([NH+]1CCC(C2=CC=CC=C2)(C3=CC=CC=C3)CC1)(C)C.[Cl-]


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Reichmann H. Budipine in Parkinson's tremor. J Neurol Sci. 2006 Oct 25;248(1-2):53-5. Review. PubMed PMID: 16784759.

2: Owen JC, Whitton PS. Effects of amantadine and budipine on antidepressant drug-evoked changes in extracellular dopamine in the frontal cortex of freely moving rats. Brain Res. 2006 Oct 30;1117(1):206-12. PubMed PMID: 16996043.

3: Müller T, Kuhn W, Przuntek H. Efficacy of budipine and placebo in untreated patients with Parkinson's disease. J Neural Transm (Vienna). 2005 Aug;112(8):1015-23. PubMed PMID: 15583956.

4: Fisher A, Wang X, Cock HR, Thom M, Patsalos PN, Walker MC. Synergism between topiramate and budipine in refractory status epilepticus in the rat. Epilepsia. 2004 Nov;45(11):1300-7. PubMed PMID: 15509230.

5: Owen JC, Whitton PS. Effects of amantadine and budipine on antidepressant drug-evoked changes in extracellular 5-HT in the frontal cortex of freely moving rats. Br J Pharmacol. 2005 Jul;145(5):587-92. PubMed PMID: 15834446; PubMed Central PMCID: PMC1576170.

6: Scholz EP, Zitron E, Kiesecker C, Lueck S, Kathöfer S, Thomas D, Weretka S, Peth S, Kreye VA, Schoels W, Katus HA, Kiehn J, Karle CA. Drug binding to aromatic residues in the HERG channel pore cavity as possible explanation for acquired Long QT syndrome by antiparkinsonian drug budipine. Naunyn Schmiedebergs Arch Pharmacol. 2003 Nov;368(5):404-14. PubMed PMID: 14557918.

7: Uhr M, Ebinger M, Rosenhagen MC, Grauer MT. The anti-Parkinson drug budipine is exported actively out of the brain by P-glycoprotein in mice. Neurosci Lett. 2005 Jul 22-29;383(1-2):73-6. PubMed PMID: 15936515.

8: Przuntek H, Bittkau S, Bliesath H, Büttner U, Fuchs G, Glass J, Haller H, Klockgether T, Kraus P, Lachenmayer L, Müller D, Müller T, Rathay B, Sgonina J, Steinijans V, Teshmar E, Ulm G, Volc D. Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen. Arch Neurol. 2002 May;59(5):803-6. PubMed PMID: 12020263.

9: Müller T, Przuntek H, Krüger R, Mackowiak A. Antiapoptotic effects of budipine. J Neural Transm (Vienna). 2004 Oct;111(10-11):1365-73. PubMed PMID: 15480843.

10: Bethke TH, Merz M, Zech K, Seiberling M, Hauschke D, Heinze H, Wurst W. Dose linearity and steady state pharmacokinetics of the new antiparkinson agent budipine after oral administration. Int J Clin Pharmacol Ther. 2001 Jun;39(6):259-64. PubMed PMID: 11430634.

11: Malsch U, Bliesath H, Böther K, Ramm H, Lühmann R. [Monotherapy of Parkinson's disease with budipine. A double blind comparison with amantadine]. Fortschr Neurol Psychiatr. 2001 Feb;69(2):86-9. German. PubMed PMID: 11253562.

12: Biggs CS, Starr MS. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum. Synapse. 1999 Oct;34(1):36-46. PubMed PMID: 10459170.

13: Przuntek H, Müller T. Clinical efficacy of budipine in Parkinson's disease. J Neural Transm Suppl. 1999;56:75-82. Review. PubMed PMID: 10370903.

14: Eltze M. Multiple mechanisms of action: the pharmacological profile of budipine. J Neural Transm Suppl. 1999;56:83-105. Review. PubMed PMID: 10370904.

15: Biggs CS, Fisher A, Starr MS. The antiparkinsonian drug budipine stimulates the activity of aromatic L-amino acid decarboxylase and enhances L-DOPA-induced dopamine release in rat substantia nigra. Synapse. 1998 Nov;30(3):309-17. PubMed PMID: 9776134.